Rise of Generics and Patent Expirations Sees CPHI and P-MEC India 2013 Expand

CPHI announces that CPHI and P-MEC India, ran by leading events organiser UBM, is returning to the Bombay Convention and Exhibition Centre, Mumbai (India) 3–5 December 2013. The event will return with an increased scale, continuing its commitment to cater to all sectors of the pharma industry by co-locating with ICSE and BioPh India.

With a view to enhancing the customer experience and ROI value, CPHI India has enhanced the mobile application, now available on all mobile devices with an internet connection, designed to help attendees navigate their way around the event, drive traffic to stands and stay up to date with schedules and speaker events.

With the addition of hall 7, P-MEC will host even more exhibitors than previous years. Last year, there were 926 exhibitors present and this is expected to rise to 1000 this year to create the biggest show to date. Free online registration to attend CPHI and P-MEC India is now closed, however registration is still possible in Mumbai, the onsite fee is only INR500.

India has increasingly become a focal point of the pharmaceutical industry and is now the third largest in terms of volume. The country is fast becoming an innovation hub, increasingly matching Western standards and at the same time reducing the costs of manufacturing, showcasing the Indian pharma market's unique position and providing an optimum investment platform for international companies. Outside of the US, India has the highest number of FDA-approved facilities (546), and the Indian pharma sector received USFDA approvals for around 40% of all Abbreviated New Drug Approvals (ANDA) during January–July 2013. Further, with R&D investments rapidly advancing, coupled with the rise in generics and supergenerics, India represents a key maturing market, with CPHI and P-MEC India facilitating opportunities to drive and enhance the sector.

Ahead of the event, the UBM India pharma awards will take place on 2 December, celebrating the most innovative and dynamic areas across the Indian pharma community. Honouring companies who are driving forward industry changing initiatives, there will be awards for multiple categories including ‘Excellence in Product Development’, ‘Excellence in Contract Research’ and ‘Excellence in Packaging Development’. The evening will also host a panel discussion on ‘Moving up the Global Pharma Value Chain’, designed to inform and educate those present at the awards ceremony.

“The global pharmaceutical market has seen a significant shift during the last year, particularly as patent expirations are becoming more frequent and a potential patent cliff is shaking the industry. India, however, is thriving as the demand for generics is on the rise and companies are looking to drive down manufacturing costs. India is well positioned to accommodate increased demand, providing expertise in development and manufacturing. CPHI and P-MEC India will provide the ideal and essential platform for international and domestic suppliers and buyers to break into the market,” said Chris Kilbee, Group Director, Pharma.